Scleritis
The most likely diagnosis is C. Scleritis. This patient's presentation of severe, deep ocular pain radiating to the temple, worsening at night and with eye movement, in the context of rheumatoid arthritis, is pathognomonic for scleritis rather than the more superficial conditions listed.
Clinical Reasoning
Key Distinguishing Features
The clinical presentation provides critical diagnostic clues:
- Deep, boring ocular pain (not superficial irritation) that radiates to the temple
- Pain worse at night and with eye movement - this is highly characteristic of scleral inflammation
- Diffuse injection in a patient with established rheumatoid arthritis
- Age and systemic disease context - 51-year-old woman with RA
Why Not the Other Options?
Episcleritis (Option A) presents with mild discomfort or irritation, not severe deep pain. The episclera is superficial to the sclera, so pain does not radiate or worsen with eye movement. While episcleritis can occur in RA patients, it's typically benign and self-limited 1, 2.
Allergic and viral conjunctivitis (Options B and D) cause superficial irritation, itching, or foreign body sensation - never deep boring pain. These conditions don't worsen with eye movement and have no association with the severe pain pattern described 1.
Clinical Significance in Rheumatoid Arthritis
Scleritis is the most serious ocular complication of RA, occurring in approximately 1% of RA patients but representing a potentially vision-threatening and life-threatening condition 3, 2. RA is the leading cause of necrotizing scleritis, the most severe form 2.
Critical Associations
- Systemic vasculitis correlation: Scleritis in RA patients is associated with systemic vasculitis and carries excess mortality risk 2, 4
- Disease activity marker: Presence of scleritis often indicates poorly controlled systemic disease
- Vision-threatening: Can rapidly progress to globe perforation if untreated, particularly necrotizing forms
Immediate Management Priorities
Urgent Ophthalmology Referral
This patient requires immediate ophthalmology consultation for slit-lamp examination to:
- Confirm scleritis diagnosis
- Differentiate between diffuse, nodular, or necrotizing subtypes
- Assess for complications (peripheral ulcerative keratitis, uveitis)
Rheumatology Coordination
Close collaboration between ophthalmology and rheumatology is essential 1, 2. The presence of scleritis should prompt:
- Reassessment of RA disease activity
- Evaluation for systemic vasculitis
- Consideration of cardiovascular risk (RA patients have diabetes-equivalent cardiovascular risk) 4
Treatment Approach
For severe scleritis in RA:
- Systemic therapy is mandatory - topical treatment alone is insufficient 2, 5
- Initial treatment: Systemic corticosteroids combined with disease-modifying antirheumatic drugs (DMARDs)
- Steroid-sparing agents: Methotrexate is typically first-line DMARD 6
- Biologic therapy: For refractory cases or when conventional DMARDs fail, TNF inhibitors (particularly monoclonal antibodies like adalimumab) are highly effective 7, 6
Common Pitfalls
Do not dismiss severe ocular pain in RA patients as "just dry eye" - the quality and severity of pain distinguishes scleritis from keratoconjunctivitis sicca (dry eye), which is the most common but benign ocular manifestation in RA 3, 5.
Do not delay systemic immunosuppression - scleritis, particularly necrotizing forms, can progress rapidly to vision loss and is associated with increased mortality when part of systemic vasculitis 2.
Do not treat with topical therapy alone - unlike episcleritis, scleritis requires systemic immunosuppressive therapy to prevent complications and vision loss 2, 5.